Teva Medical Information Consulting (Shanghai) Co., Ltd.

To evaluate the safety, tolerability, and pharmacokinetics of a single dose of subcutaneous olanzapine extended-release suspension (TV-44749) in Chinese patients with schizophrenia.

Primary objective: To evaluate the effectiveness of deutetrabenazine in treating adult patients with chorea associated with Huntington's disease in the real world of China. Secondary objective: To evaluate the safety of deutetrabenazine in treating adult patients with chorea associated with Huntington's disease in the real world of China.

Schizophrenia is a debilitating, severe psychotic disorder characterized by both positive and negative symptoms with a global lifetime risk of approximately 1%. For most patients, the disease is associated with a chronic course requiring long-term antipsychotic treatment. Nonadherence and noncompliance with long-term oral medication regimens are the most important treatment issues in the treatment of schizophrenia and related disorders, resulting in many of these patients experiencing frequent relapses or exacerbations and failing to fully benefit from antipsychotic treatment. Extended-release injectable antipsychotics may improve adherence in patients with schizophrenia. Currently, oral, long-acting intramuscular (IM), and rapid-acting IM formulations of olanzapine are approved for the treatment of adults with schizophrenia. A new formulation of olanzapine extended-release suspension (TV-44749) for subcutaneous injection (sc) is intended for the treatment of schizophrenia.